Laekna (HKSE:02105) Price-to-Tangible-Book : 3.57 (As of May. 29, 2024)

View and export this data going back to 2023. Start your Free Trial

What is Laekna Price-to-Tangible-Book?

As of today (2024-05-29), Laekna's share price is HK$6.80. Laekna's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was HK$1.91. Hence, Laekna's Price to Tangible Book Ratio of today is 3.57.

The historical rank and industry rank for Laekna's Price-to-Tangible-Book or its related term are showing as below:

HKSE:02105' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.56 Med: 10.44 Max: 10.44
Current: 3.56

During the past 3 years, Laekna's highest Price to Tangible Book Ratio was 10.44. The lowest was 3.56. And the median was 10.44.

HKSE:02105's Price-to-Tangible-Book is ranked worse than
59.85% of 1218 companies
in the Biotechnology industry
Industry Median: 2.83 vs HKSE:02105: 3.56

A closely related ratio is called PB Ratio. As of today, Laekna's share price is HK$6.80. Laekna's Book Value per Sharefor the quarter that ended in Dec. 2023 was HK$2.25. Hence, Laekna's P/B Ratio of today is 3.02.

Laekna Price-to-Tangible-Book Historical Data

The historical data trend for Laekna's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laekna Price-to-Tangible-Book Chart

Laekna Annual Data

Trend

Dec21

Dec22

Dec23

Price-to-Tangible-Book

10.44

Laekna Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
Price-to-Tangible-Book	-	-	-	7.20	10.44

Competitive Comparison of Laekna's Price-to-Tangible-Book

For the Biotechnology subindustry, Laekna's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Laekna's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Laekna's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Laekna's Price-to-Tangible-Book falls into.

Laekna Price-to-Tangible-Book Calculation

Laekna's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2023 )
	=	6.80	/	1.906
	=	3.57

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Laekna Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Laekna's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Laekna (HKSE:02105) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Laekna Inc (HKSE:02105) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 987, Cailun Road, 5th Floor, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, CHN, 201203

Website

https://www.laekna.com

Laekna Inc is a science-driven, clinical-stage biotechnology company. The company has established a comprehensive R&D infrastructure to accelerate the development of molecules from discovery to registrational trials. It has initiated one clinical trial and another five clinical trials for its Core Products LAE002 and LAE001. Among these six clinical trials, three multi-regional clinical trials (MRCTs) are designed to address medical needs in the standard of care (SOC)-resistant cancers. Laekna has two Core Products and 14 other pipeline product candidates. Core Product LAE002 is an adenosine triphosphate (ATP) competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer and PD-1/PD-L1 drug-resistant solid tumors.

Executives

Gp Healthcare Capital, Inc.	2101 Beneficial owner
Shang Hai Jin Pu Yi Liao Jian Kang Gu Quan Tou Zi Ji Jin Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Shang Hai Jin Pu Yi Liao Jian Kang Gu Quan Tou Zi He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Liu Zeng	2201 Interest of corporation controlled by you
Zhong Yi Ning Bo Sheng Tai Yuan Kong Gu Ji Tuan You Xian Gong Si	2201 Interest of corporation controlled by you
Ning Bo Yao Shang Yan Chuang Si Mu Ji Jin Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Ning Bo Yao Shang Yan Chuang Shou Ren Gu Quan Tou Zi You Xian Gong Si	2201 Interest of corporation controlled by you
Ning Bo Yan Chuang Hou De Tou Zi Ji Tuan You Xian Gong Si	2201 Interest of corporation controlled by you
Bei Jing Chun Lin Xin Xi Zi Xun Zhong Xin You Xian He Huo	2201 Interest of corporation controlled by you
Bei Jing An Long Chuang Ye Tou Zi Ji Jin You Xian He Huo	2201 Interest of corporation controlled by you
Liu Ying	2201 Interest of corporation controlled by you
Guo Tou Zhao Shang Tou Zi Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Xian Jin Zhi Zao Chan Ye Tou Zi Ji Jin Er Qi You Xian He Huo	2101 Beneficial owner
Yu Yao Yang Ming Gu Quan Tou Zi Ji Jin You Xian Gong Si	2101 Beneficial owner
Futu Trustee Limited	2301 Trustee

Laekna (HKSE:02105) Headlines

No Headlines